Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Stroke. 2018 Feb 13;49(3):718–726. doi: 10.1161/STROKEAHA.117.019664

Figure 1.

Figure 1

MAGL inhibitor JZL184 reduces infarct volume and improves sensorimotor impairment after ET-1-induced stroke. A, Basic experimental scheme. JZL184 (16 mg/kg) or vehicle was administered i.p. 1 h after ET-1-induced stroke and all read-out parameters were evaluated at the indicated time points. B, Representative T2-weighted MR images show smaller infarct size in JZL184-treated rats than in vehicle-treated rats at 1 d after ET-1-induced ischemic stroke (top). Representative cresyl violet-stained coronal sections in SHR at 7 d after ET-1-induced stroke (bottom). Infarct volume at 1 d after ET-1-induced stroke in SHR and WKY. Edema formation as reflected by the brain water content in the ischemic hemispheres of SHR and WKY at 1 d after ET-1-induced stroke. Data are expressed as mean ± SEM (n = 15/group for SHR and 7/group for WKY). **P < 0.01 versus vehicle, unpaired t-test. C and D, Forelimb asymmetry during spontaneous exploration assessed with cylinder test (C) and sensorimotor deficits measured by adhesive removal test (D) on day 1, 3, 7, 14 and 28 after ET-1-induced stroke in SHR. Data are expressed as mean ± SEM (n = 15/group). *P < 0.05, **P < 0.01 versus the respective vehicle group, two-way ANOVA followed by Bonferroni’s multiple comparisons test.